HBcrAg predicts hepatocellular carcinoma development: An analysis using time-dependent receiver operating characteristics

Journal of Hepatology

Volumn 65, Issue 1, 2016, Pages 48-56

  Tada, Toshifumi ^a   Kumada, Takashi ^a   Toyoda, Hidenori ^a   Kiriyama, Seiki ^a   Tanikawa, Makoto ^a   Hisanaga, Yasuhiro ^a   Kanamori, Akira ^a   Kitabatake, Shusuke ^a   Yama, Tsuyoki ^a   Tanaka, Junko ^b  

^a OGAKI MUNICIPAL HOSPITAL   (Japan)

^b HIROSHIMA UNIVERSITY   (Japan)

Author keywords

Hepatitis B; Hepatitis B virus core related antigen; Hepatocellular carcinoma; Time dependent receiver operating characteristic

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ALPHA FETOPROTEIN; ASPARTATE AMINOTRANSFERASE; GAMMA GLUTAMYLTRANSFERASE; HEPATITIS B ANTIGEN; HEPATITIS B CORE ANTIGEN; HEPATITIS B CORE RELATED ANTIGEN; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; INTERFERON; UNCLASSIFIED DRUG; VIRUS DNA;

ADULT; AGED; ARTICLE; CHRONIC HEPATITIS B; FEMALE; HEPATITIS B VIRUS; HUMAN; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; THROMBOCYTE COUNT; LIVER TUMOR; RISK FACTOR;

CARCINOMA, HEPATOCELLULAR; DNA, VIRAL; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LIVER NEOPLASMS; RISK FACTORS; ROC CURVE;

EID: 84964812004     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2016.03.013     Document Type: Article

References (46)

1. C.L. Lai, V. Ratziu, M.F. Yuen, and T. Poynard Viral hepatitis B Lancet 362 2003 2089 2094
2. D. Lavanchy Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures J Viral Hepat 11 2004 97 107
3. R.P. Beasley, L.Y. Hwang, C.C. Lin, and C.S. Chien Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22,707 men in Taiwan Lancet 2 1981 1129 1133
4. W. Szmuness Hepatocellular carcinoma and the hepatitis B virus: evidence for a causal association Prog Med Virol 24 1978 40 69
5. V.K. Rustgi Epidemiology of hepatocellular carcinoma Gastroenterol Clin North Am 16 1987 545 551
6. K. Kiyosawa, T. Umemura, T. Ichijo, A. Matsumoto, K. Yoshizawa, A. Gad, and et al. Hepatocellular carcinoma: recent trends in Japan Gastroenterology 127 2004 S17 S26
7. C.J. Chen, M.W. Yu, and Y.F. Liaw Epidemiological characteristics and risk factors of hepatocellular carcinoma J Gastroenterol Hepatol 12 1997 S294 S308
8. Y.S. Hsu, R.N. Chien, C.T. Yeh, I.S. Sheen, H.Y. Chiou, C.M. Chu, and et al. Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B Hepatology 35 2002 1522 1527
9. J.H. Kao, P.J. Chen, M.Y. Lai, and D.S. Chen Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B Gastroenterology 118 2000 554 559
10. M.F. Yuen, Y. Tanaka, D.Y. Fong, J. Fung, D.K. Wong, J.C. Yuen, and et al. Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B J Hepatol 50 2009 80 88
11. H. Kato, E. Orito, F. Sugauchi, R. Ueda, R.G. Gish, S. Usuda, and et al. Determination of hepatitis B virus genotype G by polymerase chain reaction with hemi-nested primers J Virol Methods 98 2001 153 159
12. F. Suzuki, H. Miyakoshi, M. Kobayashi, and H. Kumada Correlation between serum hepatitis B virus core-related antigen and intrahepatic covalently closed circular DNA in chronic hepatitis B patients J Med Virol 81 2009 27 33
13. A. Matsumoto, E. Tanaka, M. Minami, T. Okanoue, H. Yatsuhashi, S. Nagaoka, and et al. Low serum level of hepatitis B core-related antigen indicates unlikely reactivation of hepatitis after cessation of lamivudine therapy Hepatol Res 37 2007 661 666
14. T. Hosaka, F. Suzuki, M. Kobayashi, M. Hirakawa, Y. Kawamura, H. Yatsuji, and et al. HBcrAg is a predictor of post-treatment recurrence of hepatocellular carcinoma during antiviral therapy Liver Int 30 2010 1461 1470
15. A.S. Lok, and B.J. McMahon Chronic hepatitis B: update 2009 Hepatology 50 2009 661 662
16. European Association for the Study of the Liver EASL clinical practice guidelines: management of chronic hepatitis B virus infection J Hepatol 57 2012 167 185
17. Yun-Fan Liaw, Jia-Horng Kao, Teerha Piratvisuth, Henry Lik Yuen Chan, Rong-Nan Chien, Chun-Jen Liu, and et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update Hepatol Int 6 2012 531 561
18. T. Hosaka, F. Suzuki, M. Kobayashi, Y. Seko, Y. Kawamura, H. Sezaki, and et al. Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection Hepatology 58 2013 98 107
19. T. Kumada, H. Toyoda, T. Tada, S. Kiriyama, M. Tanikawa, Y. Hisanaga, and et al. Effect of nucleos(t)ide analogue therapy on hepatocarcinogenesis in chronic hepatitis B patients: a propensity score analysis J Hepatol 58 2013 427 433
20. P.J. Heagerty, and Y. Zheng Survival model predictive accuracy and ROC curves Biometrics 61 2005 92 105
21. C.W. Lin, C.C. Lin, L.R. Mo, C.Y. Chang, D.S. Perng, C.C. Hsu, and et al. Heavy alcohol consumption increases the incidence of hepatocellular carcinoma in hepatitis B virus-related cirrhosis J Hepatol 58 2013 730 735
22. Y. Li, Y. Chen, and Y. Zhao The diagnostic value of the FIB-4 index for staging hepatitis B-related fibrosis: a meta-analysis PLoS One 9 2014 e105728
23. B.K. Kim, Y. Kim do, J.Y. Park, S.H. Ahn, C.Y. Chon, J.K. Kim, and et al. Validation of FIB-4 and comparison with other simple noninvasive indices for predicting liver fibrosis and cirrhosis in hepatitis B virus-infected patients Liver Int 30 2010 546 553
24. The Japan Society of Hepatology. Surveillance algorithm and diagnostic algorithm for hepatocellular carcinoma: clinical practice guidelines for hepatocellular carcinoma Hepatol Res 40 2010 6 7
25. J. Bruix, and M. Sherman Management of hepatocellular carcinoma Hepatology 42 2005 1208 1236
26. J. Bruix, and M. Sherman Management ofhepatocellular carcinoma: an update Hepatology 53 2011 1020 1022
27. T. Kimura, A. Rokuhara, A. Matsumoto, S. Yagi, E. Tanaka, K. Kiyosawa, and et al. New enzyme immunoassay for detection of hepatitis B virus core antigen (HBcAg) and relation between levels of HBcAg and HBV DNA J Clin Microbiol 41 2003 1901 1906
28. D.K. Wong, Y. Tanaka, C.L. Lai, M. Mizokami, J. Fung, and M.F. Yuen Hepatitis B virus core-related antigens as markers for monitoring chronic hepatitis B infection J Clin Microbiol 45 2007 3942 3947
29. C.J. Liu, P.J. Chen, M.Y. Lai, J.H. Kao, and D.S. Chen Evolution of precore/core promoter mutations in hepatitis B carriers with hepatitis B e antigen seroreversion J Med Virol 74 2004 237 245
30. J.H. Kao, N.H. Wu, P.J. Chen, M.Y. Lai, and D.S. Chen Hepatitis B genotypes and the response to interferon therapy J Hepatol 33 2000 998 1002
31. T.C. Tseng, C.J. Liu, H.C. Yang, T.H. Su, C.C. Wang, C.L. Chen, and et al. High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load Gastroenterology 142 2012 1140 1149
32. C.J. Chen, H.I. Yang, J. Su, C.L. Jen, S.L. You, S.N. Lu, and et al. REVEAL-HBV Study Group. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level JAMA 295 2006 65 73
33. H.L. Chan, A. Thompson, M. Martinot-Peignoux, T. Piratvisuth, M. Cornberg, M.R. Brunetto, and et al. Hepatitis B surface antigen quantification: why and how to use it in 2011 - A core group report J Hepatol 55 2011 1121 1131
34. T.C. Tseng, C.J. Liu, H.C. Yang, T.H. Su, C.C. Wang, C.L. Chen, and et al. Serum hepatitis B surface antigen levels help predict disease progression in patients with low hepatitis B virus loads Hepatology 57 2013 441 450
35. A. Kusakabe, Y. Tanaka, M. Inoue, F. Kurbanov, K. Tatematsu, S. Nojiri, and et al. A population-based cohort study for the risk factors of HCC among hepatitis B virus mono-infected subjects in Japan J Gastroenterol 46 2011 117 124
36. K.S. Jung, J.Y. Park, Y.E. Chon, H.S. Kim, W. Kang, B.K. Kim, and et al. Clinical outcomes and predictors for relapse after cessation of oral antiviral treatment in chronic hepatitis B patients J Gastroenterol 2015 [Epub ahead of print]
37. Y. Kanda Investigation of the freely available easy-to-use software 'EZR' for medical statistics Bone Marrow Transplant 48 2013 452 458
38. Drafting Committee for Hepatitis Management Guidelines and the Japan Society of Hepatology. JSH guidelines for the management of hepatitis B virus infection Hepatol Res 44 2014 1 58
39. T. Kimura, A. Rokuhara, Y. Sakamoto, S. Yagi, E. Tanaka, K. Kiyosawa, and et al. Sensitive enzyme immunoassay for hepatitis B virus core-related antigens and their correlation to virus load J Clin Microbiol 40 2002 439 445
40. M. Honda, T. Shirasaki, T. Terashima, K. Kawaguchi, M. Nakamura, N. Oishi, and et al. HBcrAg during nucleos(t)ide analog therapy are related to intra-hepatic HBV replication and development of hepatocellular carcinoma J Infect Dis 2015 [Epub ahead of print]
41. H.I. Yang, S.H. Yeh, P.J. Chen, U.H. Iloeje, C.L. Jen, J. Su, and et al. Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma J Natl Cancer Inst 100 2008 1134 1143
42. C.J. Liu, B.F. Chen, P.J. Chen, M.Y. Lai, W.L. Huang, J.H. Kao, and et al. Role of hepatitis B viral load and basal core promoter mutation in hepatocellular carcinoma in hepatitis B carriers J Infect Dis 193 2006 1258 1265
43. Y.C. Chou, M.W. Yu, C.F. Wu, S.Y. Yang, C.L. Lin, C.J. Liu, and et al. Temporal relationship between hepatitis B virus enhancer II/basal core promoter sequence variation and risk of hepatocellular carcinoma Gut 57 2008 91 97
44. T.C. Tseng, C.J. Liu, H.C. Yang, C.L. Chen, W.T. Yang, and C.S. Tsai Higher proportion of viral basal core promoter mutant increases the risk of liver cirrhosis in hepatitis B carriers Gut 64 2015 292 302
45. M.R. Teli, C.P. Day, A.D. Burt, M.K. Bennett, and O.F. James Determinants of progression to cirrhosis or fibrosis in pure alcoholic fatty liver Lancet 346 1995 987 990
46. S. Bellentani, G. Saccoccio, G. Costa, C. Tiribelli, F. Manenti, M. Sodde, and et al. Drinking habits as cofactors of risk for alcohol induced liver damage. The Dionysos Study Group Gut 41 1997 845 850